Cusatuzumab (CD70/TNFSF7) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-877-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG1-lambda
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
ARGX-110
Background:
Cusatuzumab is SIMPLE antibody targeting CD70, which is an immune checkpoint target involving hematological malignancies, various solid tumors, and various autoimmune diseases. cusatuzumab aims to block CD70 by killing CD70-expressing cancer cells through complement-dependent cytotoxicity, enhancing antibody-dependent cell-mediated phagocytosis and enhancing antibody-dependent cell-mediated cytotoxicity Immunological monitoring of solid tumors.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / CD70/TNFSF7 [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.